{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T20:49:13Z","timestamp":1794084553248,"version":"4.8.0"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","award":["P2022E3BTH"],"award-info":[{"award-number":["P2022E3BTH"]}],"id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"AIRC Foundation for Cancer Research","doi-asserted-by":"publisher","award":["IG 2023 - ID 29286"],"award-info":[{"award-number":["IG 2023 - ID 29286"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004710","name":"Fondazione Umberto Veronesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ctrv.2026.103202","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T23:25:22Z","timestamp":1787095522000},"page":"103202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["From drug response to resistance evolution: Leveraging 3D cancer models for functional precision oncology"],"prefix":"10.1016","volume":"150","author":[{"given":"Alena","family":"Opattova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie Jean","family":"Znidericz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Chiabotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi","family":"Buzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Arena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ctrv.2026.103202_bb0005","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103202_bb0010","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","article-title":"Targeting replication stress in cancer therapy","volume":"22","author":"da Costa","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103202_bb0015","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41573-024-00979-4","article-title":"Targeting ROS in cancer: rationale and strategies","volume":"23","author":"Glorieux","year":"2024","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103202_bb0020","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12943-024-02119-3","article-title":"Altered metabolism in cancer: insights into energy pathways and therapeutic targets","volume":"23","author":"Tufail","year":"2024","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103202_bb0025","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/mutage\/gead036","article-title":"Inhibition of homologous recombination repair by Mirin in ovarian cancer ameliorates carboplatin therapy response in vitro","volume":"40","author":"Horak","year":"2025","journal-title":"Mutagenesis"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103202_bb0030","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ajpath.2015.01.016","article-title":"Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements","volume":"185","author":"Delitto","year":"2015","journal-title":"Am J Pathol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103202_bb0035","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.32604\/or.2025.067126","article-title":"Cancer 3D models: essential tools for understanding and overcoming drug resistance","volume":"33","author":"Jovanovic Stojanov","year":"2025","journal-title":"Oncol Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103202_bb0040","doi-asserted-by":"crossref","DOI":"10.1002\/cai2.102","article-title":"A comprehensive review of 3D cancer models for drug screening and translational research","volume":"3","author":"Sharma","year":"2024","journal-title":"Cancer Innov"},{"key":"10.1016\/j.ctrv.2026.103202_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2026.103190","article-title":"Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy","volume":"149","author":"Romero","year":"2026","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103202_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/cells8121620","article-title":"Spheroid culture system methods and applications for mesenchymal stem cells","volume":"8","author":"Ryu","year":"2019","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103202_bb0055","doi-asserted-by":"crossref","first-page":"20837","DOI":"10.1038\/s41598-024-69570-6","article-title":"Gradient-induced instability in tumour spheroids unveils the impact of microenvironmental nutrient changes","volume":"14","author":"Ascione","year":"2024","journal-title":"Sci Rep"},{"issue":"35","key":"10.1016\/j.ctrv.2026.103202_bb0060","doi-asserted-by":"crossref","first-page":"9037","DOI":"10.1016\/j.biomaterials.2012.08.052","article-title":"Effect of homotypic and heterotypic interaction in 3D on the E-selectin mediated adhesive properties of breast cancer cell lines","volume":"33","author":"Chandrasekaran","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.ctrv.2026.103202_bb0065","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-13-95","article-title":"3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing","volume":"13","author":"Longati","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2026.103202_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.123184","article-title":"Multicellular tumor spheroids: a convenient in vitro model for translational cancer research","volume":"358","author":"Patel","year":"2024","journal-title":"Life Sci"},{"key":"10.1016\/j.ctrv.2026.103202_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.649949","article-title":"Heterotypic tumor spheroids in agitation-based cultures: a scaffold-free cell model that sustains long-term survival of endothelial cells","volume":"9","author":"Franchi-Mendes","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103202_bb0080","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.medj.2024.08.010","article-title":"Patient-derived organoids in precision cancer medicine","volume":"5","author":"Tong","year":"2024","journal-title":"Medicine"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103202_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2020.118808","article-title":"Patients lung derived tumoroids (PLDTs) to model therapeutic response","volume":"1867","author":"Delom","year":"2020","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103202_bb0090","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nm.3802","article-title":"Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids","volume":"21","author":"Matano","year":"2015","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103202_bb0095","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","article-title":"Organoid profiling identifies common responders to chemotherapy in pancreatic Cancer","volume":"8","author":"Tiriac","year":"2018","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103202_bb0100","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1038\/s41467-018-05190-9","article-title":"Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics","volume":"9","author":"Li","year":"2018","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103202_bb0105","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","article-title":"Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids","volume":"174","author":"Dijkstra","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103202_bb0110","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12929-024-00994-y","article-title":"Scaffold-based 3D cell culture models in cancer research","volume":"31","author":"Abuwatfa","year":"2024","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.ctrv.2026.103202_bb0115","doi-asserted-by":"crossref","first-page":"35367","DOI":"10.1038\/srep35367","article-title":"Microenvironment complexity and matrix stiffness regulate breast cancer cell activity in a 3D in vitro model","volume":"6","author":"Cavo","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103202_bb0120","doi-asserted-by":"crossref","first-page":"8997","DOI":"10.1038\/s41598-019-45384-9","article-title":"Epithelial-mesenchymal transition of cancer cells using bioengineered hybrid scaffold composed of hydrogel\/3D-fibrous framework","volume":"9","author":"Pal","year":"2019","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103202_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023833","article-title":"Endothelial induced EMT in breast epithelial cells with stem cell properties","volume":"6","author":"Sigurdsson","year":"2011","journal-title":"PLoS One"},{"issue":"24","key":"10.1016\/j.ctrv.2026.103202_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202200866","article-title":"3D bioprinted patient-specific extracellular matrix scaffolds for soft tissue defects","volume":"11","author":"Behre","year":"2022","journal-title":"Adv Healthc Mater"},{"issue":"36","key":"10.1016\/j.ctrv.2026.103202_bb0135","doi-asserted-by":"crossref","first-page":"8843","DOI":"10.1039\/D4TB00680A","article-title":"Decellularized extracellular matrix-based bioengineered 3D breast cancer scaffolds for personalized therapy and drug screening","volume":"12","author":"Bhattacharya","year":"2024","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.ctrv.2026.103202_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119311","article-title":"3D porous chitosan-alginate scaffold stiffness promotes differential responses in prostate cancer cell lines","volume":"217","author":"Xu","year":"2019","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103202_bb0145","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1089\/ten.tec.2015.0375","article-title":"Analytic models of oxygen and nutrient diffusion, metabolism dynamics, and architecture optimization in three-dimensional tissue constructs with applications and insights in cerebral organoids","volume":"22","author":"McMurtrey","year":"2016","journal-title":"Tissue Eng Part C Methods"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103202_bb0150","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1038\/s41598-018-21075-9","article-title":"A microvascularized tumor-mimetic platform for assessing anti-cancer drug efficacy","volume":"8","author":"Pradhan","year":"2018","journal-title":"Sci Rep"},{"issue":"21","key":"10.1016\/j.ctrv.2026.103202_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202000880","article-title":"High-throughput tumor-on-a-chip platform to study tumor-stroma interactions and drug pharmacokinetics","volume":"9","author":"Chi","year":"2020","journal-title":"Adv Healthc Mater"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103202_bb0160","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41378-025-01028-9","article-title":"A microfluidic platform for the co-culturing of microtissues with continuously recirculating suspension cells","volume":"11","author":"Lohasz","year":"2025","journal-title":"Microsyst Nanoeng."},{"issue":"1","key":"10.1016\/j.ctrv.2026.103202_bb0165","doi-asserted-by":"crossref","DOI":"10.1038\/s41378-026-01215-2","article-title":"Functional drug screening of tumor organoids on an active-matrix digital microfluidic chip for cancer precision medicine","volume":"12","author":"Sun","year":"2026","journal-title":"Microsyst Nanoeng"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103202_bb0170","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1038\/s41467-020-19058-4","article-title":"Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids","volume":"11","author":"Schuster","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103202_bb0175","doi-asserted-by":"crossref","DOI":"10.1186\/s43556-025-00352-w","article-title":"Drug resistance in cancer: molecular mechanisms and emerging treatment strategies","volume":"6","author":"Li","year":"2025","journal-title":"Mol Biomed"},{"issue":"20","key":"10.1016\/j.ctrv.2026.103202_bb0180","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202400203","article-title":"Fluorescence-guided spatial drug screening in 3D colorectal cancer spheroids","volume":"13","author":"Yau","year":"2024","journal-title":"Adv Healthc Mater"},{"issue":"18","key":"10.1016\/j.ctrv.2026.103202_bb0185","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1158\/0008-5472.CAN-14-0663","article-title":"Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer","volume":"74","author":"Walsh","year":"2014","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103202_bb0190","first-page":"1155","article-title":"Colorectal cancer organoid models uncover oxaliplatin-resistant mechanisms at single cell resolution","volume":"45","author":"Chen","year":"2022","journal-title":"Cell Oncol (Dordr)"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103202_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.113801","article-title":"Impact of treatment history on drug resistance of metastatic colorectal cancer organoids","volume":"28","author":"Huismans","year":"2025","journal-title":"iScience"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103202_bb0200","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1158\/1078-0432.CCR-19-2409","article-title":"A subset of colorectal cancers with cross-sensitivity to olaparib and oxaliplatin","volume":"26","author":"Arena","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103202_bb0205","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/s12951-024-02625-y","article-title":"3D stem-like spheroids-on-a-chip for personalized combinatorial drug testing in oral cancer","volume":"22","author":"Mehta","year":"2024","journal-title":"J Nanobiotechnology"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103202_bb0210","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13046-021-01981-z","article-title":"Preclinical models as patients\u2019 avatars for precision medicine in colorectal cancer: past and future challenges","volume":"40","author":"Durinikova","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103202_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113735","article-title":"Pre-existing subclones determine radioresistance in rectal cancer organoids","volume":"43","author":"Andel","year":"2024","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103202_bb0220","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1038\/s41598-024-83989-x","article-title":"Diffusion Smart-seq3 of breast cancer spheroids to explore spatial tumor biology and test evolutionary principles of tumor heterogeneity","volume":"15","author":"Cougnoux","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103202_bb0225","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s12885-020-06803-7","article-title":"Enhanced antitumor efficacy in colon cancer using EGF functionalized PLGA nanoparticles loaded with 5-Fluorouracil and perfluorocarbon","volume":"20","author":"Wu","year":"2020","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103202_bb0230","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1021\/acs.molpharmaceut.2c00164","article-title":"Sequential dual delivery system based on siCOX-2-loaded gold nanostar and thermal-sensitive liposomes overcome hypoxia-mediated multidrug resistance in tumors","volume":"19","author":"Huang","year":"2022","journal-title":"Mol Pharm"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103202_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174119","article-title":"Phototherapeutic induction of immunogenic cell death and CD8+ T cell-granzyme B mediated cytolysis in human lung cancer cells and organoids","volume":"14","author":"Valanciute","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2026.103202_bb0240","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.addr.2014.03.001","article-title":"3D cell culture systems modeling tumor growth determinants in cancer target discovery","volume":"69\u201370","author":"Thoma","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103202_bb0245","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41596-019-0232-9","article-title":"Tumor organoid-T-cell coculture systems","volume":"15","author":"Cattaneo","year":"2020","journal-title":"Nat Protoc"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103202_bb0250","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-026-07706-0","article-title":"Analysis of the tumor reactivity of autologous TILs and allogeneic gammadelta T cells via tumor organoid-immune cell coculture","volume":"24","author":"Su","year":"2026","journal-title":"J Transl Med"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103202_bb0255","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-014644","article-title":"Correlation between recognition of autologous tumor organoids by tumor-infiltrating lymphocytes from metastatic epithelial cancers and clinical response","volume":"14","author":"Gustafson","year":"2026","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103202_bb0260","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","article-title":"Organoid modeling of the tumor immune microenvironment","volume":"175","author":"Neal","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103202_bb0265","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/boc.202100003","article-title":"A new pancreatic adenocarcinoma-derived organoid model of acquired chemoresistance to FOLFIRINOX: first insight of the underlying mechanisms","volume":"114","author":"Hadj Bachir","year":"2022","journal-title":"Biol Cell"},{"issue":"15","key":"10.1016\/j.ctrv.2026.103202_bb0270","doi-asserted-by":"crossref","first-page":"6928","DOI":"10.7150\/thno.43811","article-title":"Aurora-A\/SOX8\/FOXK1 signaling axis promotes chemoresistance via suppression of cell senescence and induction of glucose metabolism in ovarian cancer organoids and cells","volume":"10","author":"Sun","year":"2020","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103202_bb0275","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/cac2.12274","article-title":"The Fibrillin-1\/VEGFR2\/STAT2 signaling axis promotes chemoresistance via modulating glycolysis and angiogenesis in ovarian cancer organoids and cells","volume":"42","author":"Wang","year":"2022","journal-title":"Cancer Commun (Lond)"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103202_bb0280","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s13402-022-00707-3","article-title":"Heterogeneity, inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer","volume":"45","author":"Xian","year":"2022","journal-title":"Cell Oncol (Dordr)"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103202_bb0285","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1158\/1078-0432.CCR-23-3980","article-title":"Targeting AKR1B10 by drug repurposing with epalrestat overcomes chemoresistance in non-small cell lung Cancer patient-derived tumor organoids","volume":"30","author":"Suvilesh","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103202_bb0290","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.celrep.2019.10.068","article-title":"CREB5 promotes resistance to androgen-receptor antagonists and androgen deprivation in prostate cancer","volume":"29","author":"Hwang","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.ctrv.2026.103202_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118359","article-title":"Drug repurposing identifies proteasome inhibitors as antiproliferative agents counteracting inflammation-driven chemoresistance in triple-negative breast cancer organoids","volume":"190","author":"Sari","year":"2025","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103202_bb0300","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jcmgh.2021.10.008","article-title":"Disease modeling on tumor organoids implicates AURKA as a therapeutic target in liver metastatic colorectal cancer","volume":"13","author":"Boos","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103202_bb0305","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000437","article-title":"Inhibition of the transmembrane transporter ABCB1 overcomes resistance to doxorubicin in patient-derived organoid models of HCC","volume":"8","author":"Blukacz","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ctrv.2026.103202_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2026.101354","article-title":"Single-cell transcriptome analysis of patient-derived organoids captures inter- and intratumor heterogeneity and uncovers targetable pathways in high grade serous ovarian cancer","volume":"85","author":"Pieraccioli","year":"2026","journal-title":"Drug Resist Updat"},{"issue":"31","key":"10.1016\/j.ctrv.2026.103202_bb0315","article-title":"Patient-derived tumor organoids combined with function-associated ScRNA-Seq for dissecting the local immune response of lung Cancer","volume":"11","author":"Liu","year":"2024","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103202_bb0320","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-022-02591-z","article-title":"Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction","volume":"42","author":"Papaccio","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103202_bb0325","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s43018-023-00715-8","article-title":"Targeted activation of ferroptosis in colorectal cancer via LGR4 targeting overcomes acquired drug resistance","volume":"5","author":"Zheng","year":"2024","journal-title":"Nat Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103202_bb0330","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/s41418-024-01263-z","article-title":"FSP1 inhibition enhances olaparib sensitivity in BRCA-proficient ovarian cancer patients via a nonferroptosis mechanism","volume":"31","author":"Miao","year":"2024","journal-title":"Cell Death Differ"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103202_bb0335","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13046-023-02671-8","article-title":"Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo\/YAP1\/c-Jun axis","volume":"42","author":"Zhou","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103202_bb0340","article-title":"Empowering clinical decision making in oligometastatic colorectal cancer: the potential role of drug screening of patient-derived organoids","volume":"5","author":"Mauri","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"513","key":"10.1016\/j.ctrv.2026.103202_bb0345","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay2574","article-title":"Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients","volume":"11","author":"Ooft","year":"2019","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103202_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100103","article-title":"Prospective experimental treatment of colorectal cancer patients based on organoid drug responses","volume":"6","author":"Ooft","year":"2021","journal-title":"ESMO Open"},{"issue":"13","key":"10.1016\/j.ctrv.2026.103202_bb0355","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14133252","article-title":"A RAS-independent biomarker panel to reliably predict response to MEK inhibition in colorectal cancer","volume":"14","author":"Pfohl","year":"2022","journal-title":"Cancers (Basel)."},{"issue":"1","key":"10.1016\/j.ctrv.2026.103202_bb0360","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-026-03699-2","article-title":"BRAF(V600E) patient derived colon cancer organoids identify biomarkers of response to EGFR and BRAF inhibition and replicate clinical data","volume":"45","author":"Kotarac","year":"2026","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103202_bb0365","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1038\/s41467-024-48616-3","article-title":"Drug screening on digital microfluidics for cancer precision medicine","volume":"15","author":"Zhai","year":"2024","journal-title":"Nat Commun"},{"issue":"14","key":"10.1016\/j.ctrv.2026.103202_bb0370","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1158\/1078-0432.CCR-20-0073","article-title":"Medium-throughput drug screening of patient-derived organoids from colorectal peritoneal metastases to direct personalized therapy","volume":"26","author":"Narasimhan","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103202_bb0375","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/SLA.0000000000005558","article-title":"Pancreatic cancer patient-derived organoids can predict response to neoadjuvant chemotherapy","volume":"276","author":"Demyan","year":"2022","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103202_bb0380","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13046-024-02980-6","article-title":"Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response","volume":"43","author":"Smabers","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.ctrv.2026.103202_bb0385","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17142291","article-title":"Establishment of human lung cancer organoids using small biopsy and surgical tissues","volume":"17","author":"Hwang","year":"2025","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ctrv.2026.103202_bb0390","doi-asserted-by":"crossref","DOI":"10.1155\/ijbc\/6534449","article-title":"Establishment of breast cancer organoids: a systematic review and meta-analysis","volume":"2026","author":"Rocha","year":"2026","journal-title":"Int J Breast Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103202_bb0395","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.stem.2024.08.010","article-title":"The landscape of drug sensitivity and resistance in sarcoma","volume":"31","author":"Al Shihabi","year":"2024","journal-title":"Cell Stem Cell"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103202_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2025.104039","article-title":"Protocol for generation and utilization of patient-derived organoids from multimodal specimen","volume":"6","author":"Kang","year":"2025","journal-title":"STAR Protoc."},{"issue":"7630","key":"10.1016\/j.ctrv.2026.103202_bb0405","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nature20168","article-title":"Designer matrices for intestinal stem cell and organoid culture","volume":"539","author":"Gjorevski","year":"2016","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103202_bb0410","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1002\/pmic.200900758","article-title":"Matrigel: a complex protein mixture required for optimal growth of cell culture","volume":"10","author":"Hughes","year":"2010","journal-title":"Proteomics"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103202_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2026.104486","article-title":"Protocol for generating and characterizing Matrigel-free prostate cancer patient-derived organoids","volume":"7","author":"Dolgos","year":"2026","journal-title":"STAR Protoc"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103202_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116352","article-title":"Single-cell analysis uncovers preserved prostate cancer lineages and universally altered pathways in Matrigel-free patient-derived organoids","volume":"44","author":"Dolgos","year":"2025","journal-title":"Cell Rep"},{"issue":"6378","key":"10.1016\/j.ctrv.2026.103202_bb0425","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1126\/science.aao2774","article-title":"Patient-derived organoids model treatment response of metastatic gastrointestinal cancers","volume":"359","author":"Vlachogiannis","year":"2018","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103202_bb0430","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41698-025-01082-6","article-title":"PharmaFormer predicts clinical drug responses through transfer learning guided by patient derived organoid","volume":"9","author":"Zhou","year":"2025","journal-title":"npj Precis Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:30:10Z","timestamp":1793316610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226001167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":86,"alternative-id":["S0305737226001167"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103202","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From drug response to resistance evolution: Leveraging 3D cancer models for functional precision oncology","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103202","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103202"}}